about
Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005.Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China.Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.Enterovirus infections of the central nervous system.Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June 2009-February 2011.Synthesis of novel purine-based coxsackievirus inhibitors bearing polycylic substituents at the N-9 position.Recent advancement in flavivirus vaccine development.Oral delivery of pathogens from the intestine to the nervous system.Environmental Surveillance of Polioviruses in Rio de Janeiro, Brazil, in Support to the Activities of Global Polio Eradication Initiative.Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management.Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.Future of polio vaccines.Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary.Role of environmental poliovirus surveillance in global polio eradication and beyond.Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature.Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization.Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.The costs of future polio risk management policies.Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.Applying the Concept of Peptide Uniqueness to Anti-Polio Vaccination.Nucleobase but not Sugar Fidelity is Maintained in the Sabin I RNA-Dependent RNA Polymerase.Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar.Detection of Enteroviruses in Influent and Effluent Flow Samples from Wastewater Treatment Plants in Italy.Clinical and enterovirus findings associated with acute flaccid paralysis in the Republic of Korea during the recent decade.Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.Eradicating polio: A balancing act.Recombinant Vaccines: Development, Production, and ApplicationNewcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
P2860
Q24559785-AC927EA3-9953-462D-8BFA-38074928BA45Q24682487-AD185F57-4098-403A-8830-58F1D03A06EDQ30840117-838901F1-0EC8-4FA5-9ACE-5DB1AEE36477Q33827773-FA9BD741-03DC-41B3-B831-F70E08C7A266Q33899399-4ED38BA1-605E-4045-81CB-390413DD272AQ34045658-67173CB1-DD68-4F87-99D9-F16D44409AABQ34697319-7EEEC538-76F0-47D3-B5AC-97BE9579ABD6Q35099564-EB1AC43C-E01D-4DE7-A010-9EE1AF5DFDD2Q35126871-C80EA6D6-3DAA-4152-8456-7ED220DBA233Q35728621-AAEDE905-A573-4EDE-8C4B-D843E98673BFQ35809225-9F6E7088-6ED4-4A41-872F-637C4D257AE1Q36577059-48338FCB-DC35-4248-9437-16D925E3F491Q36690341-608E28EB-A3B0-472B-B64C-7D474A5DBD4FQ36899024-51D3269F-32DF-4261-849E-3BE7D041881CQ37001439-90089E8C-0423-4C50-BBD3-0CB564F1951AQ37395077-85FA9BD6-B42B-482A-808C-85D93C78A1CBQ37450453-F24D532D-43CA-4D3C-A560-22E9B9B76BBAQ37743865-25CA7BE5-8037-47DF-8A6E-58ACF2A09738Q37891602-C0CBCE4B-4595-4900-954B-45F93A7D9DB8Q37919182-3A34DC6C-0C5E-49C7-B6FD-4F762405248CQ38028997-62A43B7D-B28A-4F4A-8331-91F1769F4453Q38167805-EF2895EF-B77F-4724-95EA-9BAB68F152F3Q38442337-74082F13-471E-4CF5-B8EB-CEAB3CF176CCQ40087779-69149E75-75AD-4741-B837-C4B63FA79433Q40238369-08DB8AA9-3AA9-40D2-AE9D-72CC6285253DQ40258086-87C08E14-D7DB-41C5-9DDA-F45B783A7DA9Q40269934-0D65F529-D620-4337-830B-202EAC870D8AQ41122240-0FC4C68D-7DAD-4F05-9B54-640CB5B54E18Q41169102-30D661F5-03D3-431A-BE22-BC8CC63B24F9Q41444113-B5C8C12D-FD60-4DF0-86D8-49BFDED35995Q42239195-EB82F9A3-A36E-42A0-B942-0228DD1C71D2Q42244770-6711BC2B-3C35-48A8-849C-77571660AE04Q50183859-193DC2F8-2F6F-46CB-8658-C9730EC6338EQ50907726-F69D4888-CCD3-4DFC-906B-3412B0D04930Q56936206-3E36902E-7564-4453-BA06-406014151738Q57169065-1E867C37-58E5-4388-8CB5-866ED177DFEA
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Polio eradication: the OPV paradox.
@ast
Polio eradication: the OPV paradox.
@en
type
label
Polio eradication: the OPV paradox.
@ast
Polio eradication: the OPV paradox.
@en
prefLabel
Polio eradication: the OPV paradox.
@ast
Polio eradication: the OPV paradox.
@en
P2093
P2860
P356
P1476
Polio eradication: the OPV paradox.
@en
P2093
David J Wood
Esther De Gourville
Olen M Kew
Walter R Dowdle
P2860
P304
P356
10.1002/RMV.401
P577
2003-09-01T00:00:00Z